Equity Brief · Basic Materials2026-10-27
ALMIB.PA·Basic Materials

Amoéba S.A.

I · AI Analysis

The brief

Amoéba develops technology that uses the natural biocidal capacity of the living amoeba Willaertia magna C2c Maky to treat water, surfaces, and chronic wounds [Yahoo Finance]. The company also offers an agriculture biocontrol technology for treating plant pathogens using lysed amoeba [Yahoo Finance]. Founded in 2010 and headquartered in Chassieu, France, the company employs 23 people [Yahoo Finance].

Amoéba S.A. is a French biotechnology company that develops biological products using living amoeba for water treatment, surface sanitation, and agricultural biocontrol [Yahoo Finance]. The company is in severe financial distress, with trailing-twelve-month revenue of only EUR 758,449 and a negative operating margin of -893.6%, meaning it burns roughly EUR 9 for every EUR 1 it generates [Yahoo Finance]. Sentinellis's Health Score of 3.3/10 and an Altman Z-score of -2.2 both signal significant bankruptcy risk [Sentinellis calculation].

The company is in acute financial distress with minimal revenue, massive operating losses, and negative free cash flow that consumes roughly one-quarter of its market value annually.

The brief AI analysisConfidence 5/10

Sentinellis health

Significant risks

3.3/10

7.5+ strong · 4.5–7.5 moderate · under 4.5 weak

Profitability

33% of score6.7/10
Net margin0.0%Gross margin0.0%· need ≥ 24%, the lower third of chemicals in our library

Returns on capital

no data
ROIC—· no dataReturn on equity—· no data

Growth & momentum

22% of score0.0/10
Revenue growth-80.9%· need ≥ 0%, the lower third of chemicals in our libraryOperating margin trend—· no data

Balance sheet

11% of score0.0/10
Current ratio—· no dataNet debt / EBITDA—· no dataInterest coverage-4.4x· need > 6.0xDebt / equity—· no data

Cash generation

33% of score3.3/10
Free cash flowEUR -7.0M· need positiveCash vs reported profitEUR -6.1M vs EUR -8.3M

Value creation

no data
ROIC vs cost of capital—· no data

Sentinellis calculation from the published statements — not a score reported by any data source. Each category is scored on the checks that had data; missing inputs are excluded rather than counted as failures.

Market capitalisation

EUR 28.7M

Revenue (TTM)

EUR 758,449

Explainers

How we read these numbers

Plain-English guides · no account needed

Premium · Free with any account

Revenue collapsed 80.9% in the latest reported period, raising questions about commercial viability and market acceptance of the company's amoeba-based technologies [Yahoo Finance].

1 of 5 risks in this report

Risks

5

Opportunities

3

Red flags

4

Leadership

3

11 more findings in the full report — free with any account.

Unlock the full Amoéba S.A. analysis

Create a free account to access the complete AI-generated report with inline citations.

  • 5 risks, 3 opportunities and 4 red flags — each with its source
  • 100+ financial metrics with charts and benchmarks
  • Full news summaries with source links
  • Executive team and compensation details
  • PDF export for offline use
Unlock all 12 findings3 free reports · No credit card

III · Related

You might also read

Same sector · Basic Materials — or comparable health

Want this for your watchlist?

Read three companies free. No card.

Get 3 free reports

Produced 27 Oct 2026, 10:44 UTC

Figures come from company filings and market data. The Sentinellis health score and the wording attached to it are our interpretation of those figures, not numbers the company reported.

Not investment advice and not a recommendation to buy or sell. Sentinellis holds no positions in the companies it covers, takes no payment from issuers, and has no broker referral arrangements.

How every figure and score is calculated